UroAlert - GU Oncology Weekly

July 24, 2025

Videos

Peer-to-Peer Clinical Conversations

Consensus Recommendations for ARPI Sequencing and Radioligand Therapy in mCRPC - Michael Morris

Michael J. Morris

Alan Bryce hosts Michael Morris to discuss mCRPC consensus recommendations from the 2024 US Prostate Cancer Consensus Conference.

Approaches to Patient Eligibility and Administration Timing for Nadofaragene Firadenovec - Alberto Martini

Alberto Martini

Zachary Klaassen hosts Alberto Martini to discuss optimizing patient selection for nadofaragene firadenovec, a gene therapy for BCG-unresponsive bladder cancer.

Beyond the Abstracts

Long-Term Oncological Outcomes for Patients with Non-Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin (BCG): A Comparative Analysis of Adequate versus Inadequate BCG Treatment - Beyond the Abstract

Prostate-Specific Antigen Response as a Prognostic Factor for Overall Survival in Patients with Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors - Beyond the Abstract

Conference Coverage

AUA 2025: Should I Use ctDNA to Guide Treatment Decisions Regarding Adjuvant Chemotherapy or IO Therapy after Radical Cystectomy?

AUA 2025: The Role of PSMA-Radioguided Surgery in Identifying Tumor Locatino and Local Staging in Prostate Cancer Patients Undergoing Radical Prostatectomy And Extended Lymph Node Dissection. Interim Analysis of Phase 2 Study

AUA 2025: Is TMT Really a Valid Option for All My Patients with MIBC

AUA 2025: Optimal Sequencing: My Patient Has BCG Unresponsive NMIBC and Declines Radical Cystectomy

AUA 2025: Biochemical Recurrence Management in 2025 – High-Yield Take Home Messages for the Practicing Clinician

AUA 2025: Assessing the Optimal Duration of Androgen Deprivation Therapy in Node Positive Patients Receiving Postoperative Radiotherapy: Applicability of the RADICALS-HD

Physician-Scientist Review Articles

Hydronephrosis in Patients with Bladder Cancer Undergoing Chemoradiotherapy - Expert Commentary

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Immunohistochemistry-based Subtyping of Urothelial Carcinoma - Expert Commentary

Deciphering the Molecular Landscape of Urothelial Carcinoma: Immunohistochemistry-based Subtyping Using 4 Easily Available Antibodies for Cost-effective Stratification.

Comparison of prognosis between primary and progressive muscle-invasive bladder carcinoma: A prospective analysis of long-term outcomes after radical cystectomy.

Does neoadjuvant chemotherapy and radical cystectomy in muscle-invasive bladder cancer obliterate survival differences between genders?

Intracorporeal versus extracorporeal urinary diversion during robotic radical cystectomy: outcomes from a large single-institutional study.

The role of exosomes in bladder cancer immunotherapy.

Efficacy of cisplatin-based neoadjuvant chemotherapy and risk factors for residual extravesical disease in muscle-invasive bladder cancer: insights from a nationwide cohort.

A population-based analysis of patterns of care in patients with high-risk non-muscle-invasive bladder cancer from Alberta, Canada.

Long-term outcome of transurethral laser ablation for recurrent non-muscle invasive bladder cancer: An EORTC risk-matched study.

Novel intravesical delivery systems for nonmuscle invasive bladder cancer.

Long-Term Oncological Outcomes for Patients with Non-Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin (BCG): A Comparative Analysis of Adequate versus Inadequate BCG Treatment - Beyond the Abstract

Impact of chemoradiotherapy for bladder cancer on pre-existing hydronephrosis and development of new hydronephrosis.

Hydronephrosis in Patients with Bladder Cancer Undergoing Chemoradiotherapy - Expert Commentary

Extended Outcomes of Intravesical Valrubicin and Docetaxel as Secondary Salvage Treatment for Recalcitrant High-risk Non-muscle-invasive Bladder Cancer - Expert Commentary

Johnson & Johnson Receives U.S. FDA Priority Review for TAR-200 NDA in High-Risk Non-Muscle Invasive Bladder Cancer

Assessing the Impact of Treatment Timing Protocols in Clinical Trials for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer.

Metastasis-Directed Therapy in the Management of Urothelial Carcinoma: A Systematic Review and Meta-analysis - Beyond the Abstract

Traditional and next-generation bacillus Calmette-Guérin based treatment strategies for bacillus Calmette-Guérin unresponsive non-muscle-invasive bladder cancer in the era of emerging therapies.

Organizational Impact of Systematic Urine Culture Before Bacillus Calmette Guerin (BCG) Induction Instillations - Beyond the Abstract

Perioperative Outcomes Using Template Mapping after Radical Cystectomy and Extended Lymph Node Dissection - Beyond the Abstract

Comparative Genomic Characterization of Small Cell Carcinoma of the Bladder Compared With Urothelial Carcinoma and Small Cell Lung Carcinoma - Beyond the Abstract

Penile & Urethral Cancers

Immune checkpoint inhibitor therapy for advanced HPV-related penile squamous cell carcinoma: a rare case report.

Survivin and Ki-67 immunohistochemical expression in penile squamous cell carcinoma: clinicopathological features and overall survival.

Single-port Antegrade Robotic Lymphadenectomy: A Novel Minimally Invasive Approach to Treat Lymph Nodes in Men with Penile Cancer.

Renal Cancer

Epithelial-mesenchymal transition classification based on machine learning for predicting prognosis and treatment response in clear cell renal cell carcinoma.

Advances in immunotherapy and targeted therapy for advanced clear-cell renal cell carcinoma: current strategies and future directions.

Assessing Oncologic and Functional Outcomes of 3D Image-Guided Robotic-Assisted Partial Nephrectomy (3D-IGRAPN): A Prospective Study (UroCCR-186).

Contemporary Outcomes of Robot-Assisted Partial Nephrectomy: Results from Two European Referral Institutions.

Improvements in the prognosis of patients with stage IV renal cancer according to the era of therapeutic agents: an analysis of National Cancer Registry data.

Genome-wide CRISPR/Cas9 screening identifies PTGR2 as a potential therapeutic target for sunitinib resistance in clear cell renal cell carcinoma.

Real-World Survival Outcomes of Partial Versus Radical Nephrectomy: Cause-Specific and Time-Dependent Effects.

Stereotactic Body Radiotherapy for Extracranial Oligometastatic Renal Cell Carcinoma: State of the Art and Future Perspectives.

FDA pooled analysis of OS according to depth of response in frontline advanced IO RCC trials.

Immune Checkpoint Inhibitor-Induced Myositis, Myocarditis, and Myasthenia Gravis Overlap Syndrome Following Nivolumab and Ipilimumab Combination Therapy in a 60-Year-Old Male With Metastatic Renal Cell Carcinoma.

Prostate Cancer

Factors Associated with Recovery of Urinary Continence: A Multicenter Comparison of Pelvic Fascia-sparing and Standard Robotic-assisted Radical Prostatectomy.

Self-reported quality of recovery after radical prostatectomy-a prospective cohort study.

Moving from a registry to a learning health system: A case study of a Dutch prostate cancer registry.

A pilot study evaluating the safety and efficacy of En-bloc holmium laser enucleation of the prostate in patients with a history of radiation therapy or high intensity focused ultrasound for management of organ confined prostate cancer with review of the

Predicting ADC map quality from T2-weighted MRI: A deep learning approach for early quality assessment to assist point-of-care.

VISION, TheraP, LuTectomy and beyond - is there a role for lutetium therapy in biochemical recurrence?

A population-based analyses of the evolving management of cN1M0 prostate cancer in the PSMA-PET era.

Irreversible Electroporation for Prostate Tissue Ablation in Patients with Intermediate-risk Prostate Cancer: Results from the PRESERVE Trial.

Novel Therapeutic Strategies for Metastatic Prostate Cancer Care.

Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate Cancer.

Dose-response mapping of bladder and rectum in prostate cancer patients undergoing radiotherapy with and without baseline toxicity correction.

Safety and Efficacy of Tarlatamab in patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study.

Prognostic Impact of Lymph Node Yield in a Phase III Clinical Trial (NRG/RTOG 9601) of Prostate Cancer Patients Treated With Salvage Radiation Following Prostatectomy.

Deferral of systemic therapy in patients with oligorecurrent prostate cancer treated with metastasis-directed radiotherapy.

Prostate radiotherapy in patients with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis of randomised controlled trials.

[177Lu] Lu-PSMA-617 treatment for metastatic castration-resistant prostate cancer (mCRPC) with cerebral and cerebellar metastases.

Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial.

Fracture-related hospitalisations in newly diagnosed high-risk localised or metastatic hormone-sensitive prostate cancer: secondary analysis of the STAMPEDE phase 3 trials of docetaxel and zoledronic acid using healthcare systems data.

Network Analysis of Anxiety in Prostate Cancer Patients.

Prostate cancer incidence and outcomes among Vietnam veterans receiving care in the Veterans Health Administration.

Does PARP1 up-regulation correlate with PSMA expression in patients with metastatic castration-resistant prostate cancer studied with [18F]PARPi and [68Ga]PSMA PET/CT?

Radiotherapy- Versus Surgery-based Treatment Strategy in High-risk Prostate Cancer.

Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial.

Final overall survival and safety analyses of the phase 3 PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer.

Real-World Treatment Patterns and Survival in People With Metastatic Castration-Resistant Prostate Cancer Following Metastatic Hormone-Sensitive Disease Between 2020 and 2023 in the United States.

PSA Kinetics and Predictors of PSA Response in Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Receptor Signaling Inhibitors - Beyond the Abstract

Prostate-Specific Antigen Response as a Prognostic Factor for Overall Survival in Patients with Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors - Beyond the Abstract

Unplanned hospitalization among advanced prostate cancer patients by diabetes status-a population-based study.

Risk factors for low-risk prostate cancer: A retrospective cohort study within the FinRSPC trial.

Evaluating Artificial Intelligence-Assisted Prostate Biparametric MRI Interpretation: An International Multireader Study.

Circulating Tumor Cells Are Detectable and Independent of PSA and PSMA-PET Metrics in Localized High-Risk and Biochemically Recurrent Prostate Cancer.

Active Surveillance Selection and 3-Year Durability in Intermediate-Risk Prostate Cancer Following Genomic Testing - Beyond the Abstract

Eliciting the Impact of Metformin and Statins on Prostate Cancer Outcomes from a Real-life National Database Analysis - Beyond the Abstract

Targeting All Multiple Magnetic Resonance Imaging Prostate Lesions Does Not Enhance Cancer Detection: Insights from the YAU Prostate Cancer Group - Beyond the Abstract

Visceral Metastases, Platelet Dynamics, and PSA Decline: From Biomarkers to Better Outcomes in [177Lu]Lu‑PSMA‑617 Therapy in Metastatic Castration-Resistant Prostate Cancer - Beyond the Abstract

Upper Tract Tumors

Outcomes of endoscopic management of upper tract urothelial carcinoma.

Re-appraisal of Standard of Care Imaging to Identify Predictors of Treatment Outcomes among Patients with Bladder and Upper Tract Urothelial Cancers.

Testicular Cancer

Spatial transcriptomics mapping of immune cell and TGFβ signalling pathway heterogeneity in testicular germ cell tumours.

Bilateral Germ Cell Tumor of the Testis: Biological and Clinical Implications for a Stem Versus Genetic Origin of Cancers.

Can Contralateral Template Dissection be Avoided in Post-chemotherapy Retroperitoneal Lymph Node Dissection for Non-seminomatous Germ Cell Tumors?

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2025 Digital Science Press, LLC